Fusion of tumour cells with bone marrow-derived cells: A unifying explanation for metastasis

Nature Reviews Cancer

Volumn 8, Issue 5, 2008, Pages 377-386

  Pawelek, John M ^a   Chakraborty, Ashok K ^a  

^a YALE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD47 ANTIGEN; HERMES ANTIGEN; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MELANIN; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; OSTEONECTIN; PROTEIN KINASE B BETA; SCATTER FACTOR; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR TWIST; VITRONECTIN RECEPTOR;

AUTOPHAGY; B LYMPHOCYTE; BONE MARROW CELL; CELL FUSION; CELL MIGRATION; GENE EXPRESSION; HUMAN; MACROPHAGE; MELANOMA CELL; METASTASIS; MOLECULAR DYNAMICS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; TUMOR CELL;

ANIMALS; BONE MARROW CELLS; CELL FUSION; CHIMERA; HUMANS; MACROPHAGES; MICE; NEOPLASM METASTASIS; NEOPLASMS; NEOPLASTIC STEM CELLS;

EID: 42549167207     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc2371     Document Type: Review

References (176)

1. Aichel, O. in Vorträge und Aufsätze über Entvickelungsmechanik Der Organismen Chapter XIII (ed Roux, W.) 92-111 (Wilhelm Engelmann, Leipzig, 1911).
2. Pawelek, J. M. Tumour cell hybridization and metastasis revisited. Melanoma Res. 10, 507-514 (2000).
3. Pawelek, J. M. Tumour-cell fusion as a source of myeloid traits in cancer. Lancet Oncol. 6, 988-993 (2005).
4. Pawelek, J. et al. Co-opting macrophage traits in cancer progression: a consequence of tumor cell fusion? Contrib. Microbiol.13, 138-155 (2006).
5. Mekler, L. B. [A general theory of oncogenesis.] Materials of Symposia on General Immunology. The Club of Immunologists of NF Gamaleya Inst of Epidemiology and Microbiology 3, 91-100 (1968) (in Russian).
6. Mekler, L. B. [Hybridization of transformed cells with lymphocytes as 1 of the probable causes of the progression leading to the development of metastatic malignant cells.] Vestn Acad. Med. Nauk. SSR (Bulletin of the USSR Acad Med Sci) 26, 80-89 (1971) (in Russian).
7. Goldenberg,.DM. [On the progression of malignity: a hypothesis.] Klin. Wschr. 46, 898 (1968) (in German).
8. Goldenberg, D. M. & Gotz, H. On the 'human' nature of highly malignant heterotransplantable tumors of human origin. Europ. J. Cancer 4, 547-548 (1968).
9. Lagarde, A. E. & Kerbel, R. S. Somatic cell hybridization in vivo and in vitro in relation to the metastatic phenotype. Biochim. Biophys. Acta 823, 81-110 (1984).
10. Gupta, P. B., Mani, S., Yang, J., Hartwell, K. & Weinberg, R. A. The evolving portrait of cancer metastasis Cold Spring Harb. Symp. Quant. Biol. 6, 291-297 (2005).
11. Chambers, A. F., Groom, A. C. & MacDonald, I, C. Dissemination and growth of cancer cells in metastatic sites. Nature Rev. Cancer 2, 563-572 (2002).
12. Nowell, P. C. The clonal evolution of tumor cell populations. Science 194, 23-28 (1976).
13. Fidler, I. J. & Kripke, M. L. Metastasis results from preexisting variant cells within a malignant tumor. Science 197, 893-895 (1977).
14. Ma, L., Teruya-Feldstein, J. & Weinberg, R. A. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 449, 682-688 (2007).
15. Chakraborty, A. K. & Pawelek, J. M. GnT-V, macrophages, and cancer metastasis: A common link. Clin. Exp. Metastasis 20, 365-373 (2003).
16. Munzarova, M., Lauerova, L. & Capkova, J. Are advanced malignant melanoma cells hybrids between melanocytes and macrophages? Melanoma Res. 2, 127-129 (1992).
17. Chakraborty. A. K., de Freitas Sousa, J., Espreafico, E. M. & Pawelek, J. M. Human monocyte x mouse melanoma fusion hybrids express human gene. Gene 275, 103-106 (2001).
18. Duelli, D. & Lazebnik, Y. Cell-to-cell fusion as a link between viruses and cancer. Nature Rev. Cancer 7, 968-976
19. Bjerkvig, R., Tysnes, B. B., Aboody, K. S., Najbauer, J. & Terzis, A. J. Opinion: the origin of the cancer stem cell: current controversies and new insights. Nature Rev. Cancer 5, 899-904. Erratum in Nature Rev. Cancer 5, 995 (2005).
20. Sapir, A., Avinoam, O., Podbilewicz, B. & Chernomordik, L. V. Viral and developmental cell fusion mechanisms: conservation and divergence. Dev Cell. 14, 11-21 (2008).
21. Chen, E. H. & Olson, E. N. Unveiling the mechanisms of cell-cell fusion. Science 308, 369-373 (2005).
22. Vignery, A. Macrophage fusion: the making of osteoclasts and giant cells. J. Exp. Med. 202, 337-340 (2005).
23. Vignery, A. Macrophage fusion: are somatic and cancer cells possible partners? Trends Cell Biol. 4, 188-193 (2005).
24. Chen, E. H., Grote, E., Mohler. W. & Vignery, A. Cell-cell fusion. FEBS Lett. 581, 2181-2193 (2007).
25. Pajcini, K. V., Pomerantz, J. H., Alkan, O., Doyonnas, R. & Blau, H. M. Myoblasts and macrophages share molecular components that contribute to cell-cell fusion. J. Cell Biol. 180, 1005-1019 (2008).
26. Holmgren, L., Bergsmedh, A. & Spetz, A. L. Horizontal transfer of DNA by the uptake of apoptotic bodies. Vox Sang. 83 (Suppl. 1), 305-306 (2002).
27. Duelli, D. M. et al. A virus causes cancer by inducing massive chromosomal instability through cell fusion. Curr. Biol. 17, 431-437 (2007).
28. Larsson, L. I., Bjerregaard, B., Wulf-Andersen, L. & Talts, J. F. Syncytin and cancer cell1 fusions. Sci. World J. 7, 1193-1197 (2007).
29. Jin, J. & Woodgett, J. R. Chronic activation of protein kinase Bβ/Akt2 leads to multinucleation and cell fusion in human epithelial kidney cells: events associated with tumorigenesis. Oncogene 24, 5459-5470 (2005).
30. Overholtzer, M. et al. A nonapoptotic cell death process, entosis, that occurs by cell-in-cell invasion. Cell 131, 966-979 (2007).
31. Yagi, M., Miyamoto, T., Toyama, Y. & Suda, T. Role of DC-STAMP in cellular fusion of osteoclasts and macrophage giant cells. J. Bone Miner. Metab. 24, 355-358 (2006).
32. Teitelbaum, S. L. & Ross, F. P. Genetic regulation of osteoclast development and function. Nature Rev. Genet. 4, 638-649 (2003).
33. Han, X. et al. CD47, a ligand for the macrophage fusion receptor, participates in macrophage multinucleation. J. Biol. Chem. 275, 37984-37992 (2000).
34. Kajita, M. et al. Membrane-type 1 matrix metalloproteinase cleaves CD44 and promotes cell migration. J. Cell Biol. 153, 893-904 (2001).
35. Kyriakides, T. R., et al. The CC chemokine ligand, CCL2/MCP1, participates in macrophage fusion and foreign body giant cell formation. Am. J. Pathol. 165, 2157-2166 (2004).
36. Kim, M. S., Magno, C. L., Day, C. J. & Morrison, N. A. Induction of chemokines and chemokine receptors CCR2b and CCR4 in authentic human osteoclasts differentiated with RANKL and osteoclast like cells differentiated by MCP-1 and RANTES. J. Cell. Biochem. 97, 512-518 (2006).
37. Marhaba, R. & Zöller, M. CD44 in cancer progression: adhesion, migration and growth regulation. J. Mol. Histol 35, 211-231 (2004).
38. Götte, M. & Yip, G. W. Heparanase, hyaluronan, and CD44 in cancers: a breast carcinoma perspective. Cancer Res 66, 10233-10237(2006).
39. Dalerba, P. et al. Phenotypic characterization of human colorectal cancer stem cells. Proc. Natl Acad. Sci. USA 104, 10158-10163 (2007).
40. Zijlmans, H. J. et al. The absence of CCL2 expression in cervical carcinoma is associated with increased survival and loss of heterozygosity at 17q11.2. J. Pathol. 208, 507-517 (2006.
41. Baier, P. K., Eggstein, S., Wolff-Vorbeck, G., Baumgartner, U. & Hopt, U. T. Chemokines in human colorectal carcinoma. Anticancer Res. 25, 3581-3584 (2005).
42. Rendlew-Danielsen, J. M., et al. Dysregulation of CD47 and the ligands thrombospondin 1 and 2 in multiple myeloma. Br. J. Haematol. 138, 756-760 (2007).
43. Handerson, T. et al. Melanophages reside in hypermelanotic, aberrantly glycosylated tumor areas and predict improved outcome in primary cutaneous malignant melanoma. J. Cutaneous Pathol. 34, 667-738 (2007).
44. Jacobsen, B. M., et al. Spontaneous fusion with, and transformation of mouse stroma by, malignant human breast cancer epithelium. Cancer Res. 66, 8274-8279 (2006).
45. Rizvi, A. Z., et al. Bone marrow-derived cells fuse with normal and transformed intestinal stem cells. Proc. Natl Acad. Sci. USA 103, 6321-6325 (2006).
46. Mortensen, K., Lichtenberg, J., Thomsen, P. D. & Larsson, L. I. Spontaneous fusion between cancer cells and endothelial cells. Cell. Mol. Life Sci. 61, 2125-2131 (2004).
47. Bjerregaard, B., Holck, S., Christensen, I. J. & Larsson, L. I. Syncytin is involved in breast cancer-endothelial cell fusions. Cell. Mol. Life Sci. 63, 1906-1911 (2006).
48. Streubel, B. et al. Lymphoma-specific genetic aberrations in microvascular endothelial cells in B-cell lymphomas. N. Engl. J. Med. 351, 250-259 (2004).
49. Alison, M. R., Lovell, M. J., Direkze, N. C., Wright, N. A. & Poulsom, R. Stem cell plasticity and tumour formation. Eur. J. Cancer 42, 1247-1256 (2006).
50. Herzog, E. L., et al. Lung-specific nuclear reprogramming is accompanied by heterokaryon formation and Y chromosome loss following bone marrow transplantation and secondary inflammation. FASEB J. 21, 2592-12601 (2007).
51. Kerbel, R. S., Lagarde, A. E., Dennis, J. W. & Donaghue, T. P. Spontaneous fusion in vivo between normal host and tumor cells: possible contribution to tumor progression and metastasis studied with a lectin-resistant mutant tumor. Mol. Cell. Biol. 3, 523-538 (1983).
52. Chakraborty, A. K. et al. A spontaneous murine melanoma lung metastasis comprised of host x tumor hybrids. Cancer Res. 60, 2512-2519 (2000).
53. Rachkovsky, M. S. et al. Melanoma x macrophage hybrids with enhanced metastatic potential. Clin. Exp. Metastasis 16, 299-312 (1998).
54. Wiener, F., Fenyö, E. M. & Klein, G. Tumor-host cell hybrids in radiochimeras. Proc. Natl Acad. Sci. USA 7, 148-152 (1974).
55. Andersen, T. L. et al. Osteoclast nuclei of myeloma patients show chromosome translocations specific for the myeloma cell clone: a new type of cancer-host partnership? J. Pathol. 211, 10-17 (2007).
56. Chakraborty, A. et al. Donor DNA in a renal cell carcinoma metastasis from a bone marrow transplant recipient. Bone Marrow Transplant. 34, 183-186 (2004).
57. Yilmaz, Y., Lazova, R., Qumsiyeh, M., Cooper, D. & Pawelek, J. Donor Y chromosome in renal carcinoma cells of a female BMT recipient: visualization of putative BMT-tumor hybrids by FISH. Bone Marrow Transplant. 35, 1021-1024 (2005).
58. Salama, M. E., Worsham, M. J. & DePeralta-Venturina, M. Malignant papillary renal tumors with extensive clear cell change: a molecular analysis by microsatellite analysis and fluorescence in situ hybridization. Arch. Pathol. Lab. Med.127, 1176-1181 (2003).
59. Lau, L. C., Tan, P. H., Chong, T. W., Foo, K. T. & Yip, S. Cytogenetic alterations in renal tumors: a study of 38 Southeast Asian patients. Cancer Genet. Cytogenet.175, 1-7 (2007).
60. Guo, W., Lasky, J. L. 3rd & Wu, H. Cancer stem cells. Pediatr. Res. 59, 59R-64R (2006).
61. Cogle, C. R. et al. Bone marrow contributes to epithelial cancers in mice and humans as developmental mimicry. Stem Cells 25, 1881-1887 (2007).
62. Avital, I. et al. Donor-derived human bone marrow cells contribute to solid organ cancers developing after bone marrow transplantation. Stem Cells 25, 2903-2909 (2007).
63. Wiener, F., Klein, G. & Harris, H. The analysis of malignancy by cell fusion. J. Cell Sci. 15, 177-183 (1974).
64. Stanbridge, E. J. Suppression of malignancy in human cells. Nature 260, 17-20 (1976).
65. Sidebottom, E., The analysis of malignancy by cell fusion. In Vitro 16, 77-86 (1980).
66. Ramshaw, I. A., Carlsen, S., Wang, H. & Badenoch-Jones, P. The use of cell fusion to analyse factors involved in tumour cell metastasis. Int. J. Cancer 32, 471-478 (1983).
67. Harris, H. The analysis of malignancy by cell fusion: the position in 1988. Cancer Res., 48, 3302-3306 (1988).
68. Weinberg, A. S. Tumor suppressor genes. Science 254, 1138-1146 (1991).
69. Levine, A. J. In The Molecular Basis of Cancer. (eds Mendelsohn, J., Howley, P. M., Israel, M. A. & Liotta, L. A) 86-104 (WB Saunders, Philadelphia, 1995).
70. Scaletta, L. J. & Ephrussi, B. Hybridization of normal and neoplastic cells in vitro. Nature 205, 1169 (1965).
71. Defendi, V., Ephrussi, B., Koprowski, H. & Yoshida, M. C. Properties of hybrids between polyoma-transformed and normal mouse cells. Proc. Natl Acad. Sci. USA 57, 299-305 (1967).
72. Jonasson, J., Povey, S. & Harris, H. The analysis of malignancy by cell fusion. VII. Cytogenetic analysis of hybrids between malignant diploid cells and of tumours derived from them. J. Cell Sci. 24, 217-254 (1977).
73. Davidson, R. L., Ephrussi, R. L. B. & Yamamoto, K. Regulation of pigment synthesis in mammalian cells, as studied by somatic hybridization. Proc. Natl Acad. Sci. USA 56, 1437-1440 (1966).
74. Powers, T. P. & Davidson, R. L. Coordinate extinction of melanocyte-specific gene expression in hybrid cells. Som. Cell Mol. Gen. 22, 41-56 (1996).
75. Gourdeau, H. & Fournier, R. E.K, Genetic analysis of mammalian cell differentiation. Ann. Rev. Cell Biol. 6, 69-94 (1990).
76. Powers, T. P., Shows, T. B. & Davidson, R. L. Pigment-cell-specific genes from fibroblasts are transactivated after chromosomal transfer into melanoma cells. Mol. Cell Biol. 14, 1179-1190 (1994).
77. Darlington, G. J., Bernhard, H. P. & Ruddle, F. H. Human serum albumin phenotype activation in mouse hepatoma - human leukocyte cell hybrids. Science 185, 859-862 (1974).
78. Malawista, S. E. & Weiss, M. C. Expression of differentiated function in hepatoma cell hybrids: high frequency of induction of mouse albumin production in rat hepatoma-mouse lymphoblast hybrids. Proc. Natl Acad. Sci. USA 71, 927-931 (1974).
79. Giacomoni, D. Tumorigenicity and intracisternal A-particle expression of hybrids between murine myeloma and lymphocytes. Cancer Res. 39, 4481-4484 (1979).
80. Kohler, G. & Milstein, C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256, 495-497 (1975).
81. Gottesman, M. M. & Ling, V. The molecular basis of multidrug resistance in cancer: the early years of P-glycoprotein research. FEBS Lett. 580, 998-1009 (2006).
82. Lemaire, S., Van Bambeke, F., Mingeot-Leclercq, M. P. & Tulkens, P. M. Modulation of the cellular accumulation and intracellular activity of daptomycin towards phagocytized Staphylococcus aureus by the P-glycoprotein (MDR1) efflux transporter in human THP-1 macrophages and madin-darby canine kidney cells. Antimicrob. Agents Chemother. 51, 2748-2757 (2007).
83. Rachkovsky, M. & Pawelek, J. Acquired melanocyte stimulating hormone-inducible chemotaxis following macrophage fusion with Cloudman S91 melanoma cells. Cell Growth Differ. 10, 515-524 (1999).
84. Pawelek, J. et al. Altered N-glycosylation in macrophage x melanoma fusion hybrids. Cell. Mol. Biol. 45, 1011-1027 (2000).
85. Roos, E., La Riviere, G., Collard, J. G., Stukart, M. J. & De Baetselier, P. Invasiveness of T-cell hybridomas in vitro and their metastatic potential in vivo. Cancer Res. 45, 6238-6243 (1985).
86. Larizza, L., Schirrmacher, V., Stöhr, M., Pflüger, E. & Dzarlieva, R. Inheritance of immunogenicity and metastatic potential in murine cell hybrids from the T-lymphoma ESb08 and normal spleen lymphocytes. J. Natl Cancer Inst. 72, 1371-1381 (1984).
87. Larizza, L. et al. Suggestive evidence that the highly metastatic variant ESb of the T-cell lymphoma Eb is derived from spontaneous fusion with a host macrophage. Int. J. Cancer 34, 699-707 (1984).
88. Lane, T. F. & Sage, E. H. The biology of SPARC, a protein that modulates cell-matrix interactions. FASEB J. 8, 163-173 (1994).
89. Bradshaw, A. D. & Sage, E. H. SPARC, a matricellular protein that functions in cellular differentiation and tissue response to injury. J. Clin. Invest. 107, 1049-1054 (2001).
90. Martinek, N., Shahab, J., Sodek, J. & Ringuette, M. Is SPARC an evolutionarily conserved collagen chaperone? J. Dent. Res. 86, 296-305 (2007).
91. Damjanovski, S., Huynh, M. H., Motamed, K., Sage, E.H & Ringuette, M. Regulation of SPARC expression during early Xenopus development: evolutionary divergence and conservation of DNA regulatory elements between amphibians and mammals. Dev. Genes Evol. 207, 453-461 (1998).
92. Fujita, T. et al. SPARC stimulates the synthesis of OPG/OCIF, MMP-2 and DNA in human periodontal ligament cells. J. Oral Pathol. Med. 31, 345-352 (2002). Erratum in J. Oral Pathol. Med. 31, 504 (2002).
93. Mansergh, F. C. et al. Osteopenia in Sparc (osteonectin)-deficient mice: characterization of phenotypic determinants of femoral strength and changes in gene expression. Physiol. Genomics. 32, 64-73 (2007).
94. Reed, M. J. et al. Differential expression of SPARC and thrombospondin 1 in wound repair: immunolocalization and in situ hybridization. J. Histochem. Cytochem. 41, 1467-1477 (1993).
95. Charest, A. et al. Distribution of SPARC during neovascularisation of degenerative aortic stenosis. Heart 92, 1844-1849 (2006).
96. Robert, G. et al. SPARC represses E-cadherin and induces mesenchymal transition during melanoma development. Cancer Res. 66, 7516-7523 (2006).
97. Alonso, S. R. et al. A high-throughput study in melanoma identifies epithelial-mesenchymal transition as a major determinant of metastasis. Cancer Res. 67, 3450-3460 (2007).
98. Barrallo-Gimeno, A. & Nieto, M. A. The Snail genes as inducers of cell movement and survival: implications in development and cancer. Development 132, 3151-3161 (2005).
99. Chakraborty, A. K. & Yamaga, S. Differential gene expression in genetically matched mouse melanoma cells with different metastatic potential. Gene 315, 165-175 (2003).
100. Sharif, M. N. et al. Twist mediates suppression of inflammation by type I IFNs and Axl. J. Exp. Med. 203, 1891-1901 (2006).
101. Sosi, D., Richardson, J. A., Yu, K., Ornitz, D. M. & Olson, E. N. Twist regulates cytokine gene expression through a negative feedback loop that represses NF-κB activity. Cell 112, 169-180 (2003).
102. Carlson, J. A., Linette, G. P., Aplin, A., Ng, B. & Slominski, A. Melanocyte receptors: clinical implications and therapeutic relevance. Dermatol. Clin. 25, 541-557, viii-ix (2007).
103. Kanetsky, P. A. et al. Population-based study of natural variation in the melanocortin-1 receptor gene and melanoma. Cancer Res. 66, 9330-9337 (2006).
104. McGill, G. G., Haq, R., Nishimura, E. K. & Fisher, D. E. c-Met expression is regulated by Mitf in the melanocyte lineage. J. Biol. Chem. 281, 10365-10373 (2006).
105. Beuret, L. et al. Up-regulation of MET expression by α-melanocyte-stimulating hormone and MITF allows hepatocyte growth factor to protect melanocytes and melanoma cells from apoptosis. J. Biol. Chem. 282, 14140-14147 (2007).
106. Boccaccio, C. & Comoglio, P. M. Invasive growth: a MET-driven genetic programme for cancer and stem cells. Nature Rev. Cancer. 6, 637-645 (2006).
107. Chakraborty, A. K. et al. Upregulation of mRNA for the melanocortin-1 receptor but not for melanogenic proteins in macrophage x melanoma fusion hybrids exhibiting increased melanogenic and metastatic potential. Pig. Cell Res. 12, 355-366 (1999).
108. Chakraborty, A. K. et al. Expression of c-Met proto-oncogene in metastatic macrophage x melanoma fusion hybrids: implication of its possible role in MSHinduced motility. Oncol. Res. 14, 163-174 (2003).
109. Levy, C., Khaled, M. & Fisher, D. E. MITF: master regulator of melanocyte development and melanoma oncogene. Trends Mol. Med. 12, 406-414 (2006).
110. Garraway, L. A. et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436, 117-122 (2005).
111. Bronisz, A. et al. Microphthalmia-associated transcription factor interactions with 14-3-3 modulate differentiation of committed myeloid precursors. Mol. Biol. Cell 17, 3897-3906 (2006).
112. Beilmann, M. et al. Neoexpression of the c-met/hepatocyte growth factor-scatter factor receptor gene in activated monocytes. Blood 90, 4450-4458 (1997).
113. Gaasch, J. A., Bolwahnn, A. B. & Lindsey, J. S. Hepatocyte growth factor-regulated genes in differentiated RAW 264.7 osteoclast and undifferentiated cells. Gene 369, 142-152 (2006).
114. Lam, C. W., Getting, S. J. & Perretti, M. In vitro and in vivo induction of heme oxygenase 1 in mouse macrophages following melanocortin receptor activation. J. Immunol. 174, 2297-2304 (2005).
115. Lam, C. W., Perretti, M. & Getting, S. J. Melanocortin receptor signaling in RAW264.7 macrophage cell line. Peptides 27, 404-412 (2006).
116. Manna, S. K., Sarkar, A. & Sreenivasan, Y. α-Melanocyte- stimulating hormone down-regulates CXC receptors through activation of neutrophil elastase. Eur. J. Immunol. 36, 754-769 (2006).
117. Taylor, A. W. The immunomodulating neuropeptide α-melanocyte- stimulating hormone (α-MSH) suppresses LPS-stimulated TLR4 with IRAK-M in macrophages. J. Neuroimmunol. 162, 43-50 (2005).
118. Fernandes, B., Sagman, U., Auger, M., Demetrio, M. & Dennis, J. W. β1,6-branched oligosaccharides as a marker of tumor progression in human breast and colon neoplasia. Cancer Res. 51, 718-723 (1991).
119. Handerson, T., Camp, R., Harigopal, M., Rimm, D. & Pawelek, J. β1,6-Branched oligosaccharides are associated with metastasis and predict poor outcome in breast carcinoma. Clin. Cancer Res. 11, 2969-2973 (2005).
120. Seelentag, W. K. et al. Pronostic value of β1,6-branched oligosaccharides in human colorectal carcinoma. Cancer Res. 58, 5559-5564 (1998).
121. Murata, K. et al. Expression of N-acetylglucosaminyltransferase V in colorectal cancer correlates with metastasis and poor prognosis. Clin. Cancer Res. 6, 1772-1777 (2000).
122. Dosaka-Akita, H. et al. Expression of N-acetylglucosaminyltransferase V is associated with prognosis and histology in non-small cell lung cancers. Clin. Cancer Res. 10, 1773-1779 (2004).
123. Fukuda, M., Spooncer, E., Oates, J. E., Dell, A. & Klock, J. C. Structure of sialylated fucosyl lactosaminoglycan isolated from human granulocytes. J. Biol. Chem. 25 10925-10935 (1984).
124. Yamamoto, E. et al. Expression of N-acetyl- glucosaminyltransferase V in endometrial cancer correlates with poor prognosis. Br. J. Cancer 97, 1538-1544 (2007).
125. Fukuda, M., Spooncer, E., Oates, J. E., Dell, A. & Klock, J. C. Structure of sialylated fucosyl lactosaminoglycan isolated from human granulocytes. J. Biol. Chem. 259, 10925-10935 (1984).
126. Mizoguchi, A., Takasaki, S., Maeda, S. & Kobata, A. Changes in asparagine-linked sugar chains of human promyelocytic leukemic cells (HL-60) during monocytoid differentiation and myeloid differentiation. Decrease of high-molecular-weight oligosaccharides in acidic fraction. J. Biol. Chem. 259, 11949-11957 (1984).
127. Chakraborty, A. K. et al. Fusion hybrids with macrophage and melanoma cells up-regulate N-acetylglucosaminyltransferase V, β1-6 branching, and metastasis. Cell Growth Differentiation 12, 623-630 (2001).
128. Dennis, J., Waller, C. A. & Schirrmacher, V. Identification of asparagine-linked oligosaccharides involved in tumor cell adhesion to laminin and type IV collagen. J. Cell Biol. 99, 1034-1044 (1984).
129. Demetriou, M., Nabi, I. R., Coppolino, M., Dedhar, S. & Dennis, J. W. Reduced contact-inhibition and substratum adhesion in epithelial cells expressing GlcNAc-transferase, V. J. Cell Biol. 130, 383-392 (1995).
130. Saitoh, O., Wang, W. C., Lotan, R. & Fukuda, M. Differential glycosylation and cell surface expression of lysosomal membrane glycoproteins in sublines of a human colon cancer exhibiting distinct metastatic potentials. J. Biol. Chem. 267, 5700-5711 (1992).
131. Chammas, R., Veiga, S. S., Travassos, L. R. & Brentani, R. R. Functionally distinct roles for glycosylation of α and β integrin chains in cell matrix interactions. Proc. Natl Acad. Sci. USA 90, 1795-1799 (1993).
132. Zheng, M., Fang, H. & Hakomori, S. Functional role of N-glycosylation in α5β1 integrin receptor. De-N-glycosylation induces dissociation or altered association of α5 and β1 subunits and concomitant loss of fibronectin binding activity. J. Biol. Chem. 269, 12325-12331, (1994).
133. Leppa, S., Heino, J. & Jalkanen, M. Increased glycosylation of β1 integrin affects the interaction of transformed s115 mammary epithelial cells with laminin-1. Cell Growth Differ. 6, 853-861, (1995).
134. Dennis, J. W., Granovsky, M. & Warren, C. E. Glycoprotein glycosylation and cancer progression. Biochim. Biophys. Acta 1473, 21-34 (1999).
135. Yamamoto, H. et al. β1,6 N-acetyl-glucosamine bearing N-glycans in human gliomas; implications for role in regulating invasivity. Cancer Res. 60, 134-142 (2000).
136. Ochwat, D., Hoja-Lukowicz, D. & Litynska, A. N-glycoproteins bearing β1,6-branched oligosaccharides from the A375 human melanoma cell line analysed by tandem mass spectrometry. Melanoma Res. 14, 479-485 (2004).
137. Guo, H.-B., Lee, I., Kamar, M., Akiyama, S. K. & Pierce, M. Aberrant N-glycosylation of β1 integrin causes reduced α5β1 integrin clustering and stimulates cell migration. Cancer Res. 62, 6837-6845 (2002).
138. Poche, E., Litysk, A., Amoresano, A. & Casbarra, A. Glycosylation profile of integrin α3β1 changes with melanoma progression. Biochim. Biophys. Acta Mol. Cell Res. 1643, 113-123 (2003).
139. Jasiulionis, M. G., Chammas, R., Ventura, A. M., Travassos, L. R. & Brentani, R. R. α6β1-Integrin, a major cell surface carrier of β1-6-branched oligosaccharides, mediates migration of EJ-ras- transformed fibroblasts on laminin-1 independently of its glycosylation state. Cancer Res. 56, 1682-1689 (1996).
140. Giannelli, G. et al. Role of the α3β1 and α6β4 integrins in tumor invasion. Clin. Exp. Metastasis 19, 217-230 (2002).
141. Danen, E. H. J. et al. Emergence of α5β1 fibronectin-and αvβ3 vitronectin-receptor expression in melanocytic tumour progression. Histopathology 24, 249-256 (1994).
142. Natali, P. G., Nicotra, M. R., Di Filippo, F. & Bigotti, A. Expression of fibronectin, fibronectin isoforms and integrin receptors in melanocytic lesions. Br. J. Cancer 71, 1243-1247 (1995).
143. Galbraith, C. G., Yamada, K. M. & Galbraith, J. A. Polymerizing actin fibers position integrins primed to probe for adhesion sites. Science 315, 992-995 (2007).
144. Gladson, C. L. & Cheresh, D. A. Glioblastoma expression of vitronectin and the αvβ3 integrin. Adhesion mechanism for transformed glial cells. J. Clin. Invest. 88, 1924-1932 (1991).
145. Natali, P. G., et al. Clinical significance of αvβ3 integrin and intercellular adhesion molecule-1 expression in cutaneous malignant melanoma lesions. Cancer Res. 57, 1554-1560 (1997).
146. Wong, N. C. et al. αv integrins mediate adhesion and migration of breast carcinoma cell lines. Clin. Exp. Metastasis 16, 50-61 (1998).
147. Juliano, R. L. The role of β1 integrins in tumors. Semin. Cancer Biol. 4, 277-283 (1993).
148. Ammon, C. et al. Comparative analysis of integrin expression on monocyte-derived macrophages and monocyte-derived dendritic cells. Immunology 100, 364-369 (2000).
149. Aplin, A. E., Howe, A., Alahari, S. K. & Juliano, R. L. Signal transduction and signal modulation by cell adhesion receptors: the role of integrins, cadherins, immunoglobulin-cell adhesion molecules, and selectins. Pharmacol. Rev. 50, 197-263 (1998).
150. Elsegood, C. L. et al. M-CSF induces the stable interaction of cFms with αVβ3 integrin in osteoclasts. Int. J. Biochem. Cell Biol. 38, 1518-1529 (2006).
151. Shinji, H. et al. Expression and distribution of very late antigen-5 in mouse peritoneal macrophages upon ingestion of fibronectin-bound Staphylococcus aureus. Microbiol. Immunol. 51, 63-171 (2007).
152. Kurita-Taniguchi, M. et al. Molecular assembly of CD46 with CD9, α3-β1 integrin and protein tyrosine phosphatase SHP-1 in human macrophages through differentiation by GM-CSF. Mol. Immunol. 38, 689-700 (2002).
153. Chang, M. H. et al. Transthyretin interacts with the lysosome-associated membrane protein (LAMP-1) in circulation. Biochem. J. 382, 481-489 (2004).
154. Sawada, R., Lowe, J. B. & Fukuda, M. E-selectin-dependent adhesion efficiency of colonic carcinoma cells is increased by genetic manipulation of their cell surface lysosomal membrane glycoprotein-1 expression levels. J. Biol. Chem. 268, 12675-12681 (1993).
155. Sarafian, V. et al. Expression of Lamp-1 and Lamp-2 and their interactions with galectin-3 in human tumor cells. Int. J. Cancer 75, 105-111 (1998).
156. Chakraborty, A. K. & Pawelek, J. M. β1,6-branched oligosaccharides regulate melanin content and motility in macrophage-melanoma fusion hybrids. Melanoma Res. 17, 9-16 (2007).
157. Rupani, R., Handerson, T. & Pawelek, J. Co-localization of β1,6-branched oligosaccharides and coarse melanin in macrophage-melanoma fusion hybrids and human melanoma cells in vitro. Pig. Cell Res. 17, 281-288 (2004).
158. Hariri, M. et al. Biogenesis of multilamellar bodies via autophagy. Mol. Biol. Cell 11, 255-268 (2000).
159. Handerson, T. & Pawelek, J. β1,6-branched oligosaccharides and coarse vesicles: A common and pervasive phenotype in melanoma and other human cancers. Cancer Res. 63, 5363-5369 (2003).
160. Clark, W. H. et al. Current concepts of the biology of human cutaneous malignant melanoma. Adv. Cancer Res. 24, 267-338 (1977).
161. Hait, W. N., Jin, S. & Yang, J.-M. A matter of life or death (or both): understanding autophagy in cancer. Clin. Cancer Res. 12, 1961-1965 (2006).
162. Hait, W. N., Wu, H., Jin, S. & Yang, J. M. Elongation factor-2 kinase: its role in protein synthesis and autophagy. Autophagy 2, 294-296 (2006).
163. Hait, W. N., Jin, S. & Yang, J. M. Elongation factor-2 kinase regulates autophagy in human glioblastoma cells. Clin. Cancer Res. 12, 1961-1965 (2006).
164. Mathew, R., Karantza-Wadsworth, V. & White, E. Role of autophagy in cancer. Nature Rev. Cancer 7, 961-967 (2007).
165. Degenhardt, K. et al. Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. Cancer Cell 10, 51-64 (2006).
166. Levine, B. Cell biology: autophagy and cancer. Nature 446, 745-747 (2007).
167. Amer, A. O. & Swanson, M. S. Autophagy is an immediate macrophage response to Legionella pneumophila. Cell Microbiol. 7, 765-778 (2005).
168. Amer, A. O., Byrne, B. G. & Swanson, M. S. Macrophages rapidly transfer pathogens from lipid raft vacuoles to autophagosomes. Autophagy 1, 53-58 (2005).
169. Lugini, L. et al. Cannibalism of live lymphocytes by human metastatic but not primary melanoma cells. Cancer Res. 66, 3629-3638 (2006).
170. Lugini, L. et al. Potent phagocytic activity discriminates metastatic and primary human malignant melanomas: a key role of ezrin. Lab. Invest. 83, 1555-1567 (2003).
171. Damiani, M. T. & Colombo, M. I. Microfilaments and microtubules regulate recycling from phagosomes. Exp. Cell Res. 289, 152-161 (2003).
172. Coopman, P. J., Do, M. T., Thompson, E. W. & Mueller, S. C. Phagocytosis of cross-linked gelatin matrix by human breast carcinoma cells correlates with their invasive capacity. Clin. Cancer Res. 4, 507-515 (1998).
173. Montcourrier, P. et al. Characterization of very acidic phagosomes in breast cancer cells and their association with invasion. J. Cell Sci. 107, 2381-2391 (1994).
174. Houghton, J. et al. Gastric cancer originating from bone marrow-derived cells. Science 306, 1568-1571 (2004).
175. Parris, G. E. 2-Deoxy-D-glucose as a potential drug against fusogenic viruses including HIV. Med. Hypotheses 70, 776-782 (2008).
176. Halaban, R. et al. Aberrant retention of tyrosinase in the endoplasmic reticulum mediates accelerated degradation of the enzyme and contributes to the dedifferentiated phenotype of amelanotic melanoma cells. Proc. Natl Acad. Sci. USA 94, 6210-6215 (1997).